Good outcomes with Cyclosporine very low exposure with Everolimus high exposure in renal transplant patients

Journal of Nephrology

Volumn 24, Issue 5, 2011, Pages 613-618

  Bertoni, Elisabetta ^a   Larti, Aida ^a   Rosso, Giuseppina ^a   Zanazzi, Maria ^a   di Maria, Lorenzo ^a   Salvadori, Maurizio ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

CNI minimization; EGFR after transplantation; Enteric coated mycophenolic acid; Proliferation signal inhibitors

Indexed keywords

CHOLESTEROL; CYCLOSPORIN; EVEROLIMUS; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID; STEROID;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL GRAFT DYSFUNCTION; SURVIVAL RATE; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; CYCLOSPORINE; DELAYED GRAFT FUNCTION; DRUG THERAPY, COMBINATION; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ITALY; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; PROTEINURIA; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052668527     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2011.6247     Document Type: Article

References (21)

1. Chapman JR, Valantine H, Albanell J, et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc. 2007;39:2937-2950.
2. Salvadori M, Rosati A, Bock A, et al. Estimated 1-year glomerular filtration rate is the best predictor of long term graft function following renal transplant. Transplantation. 2006;81:202-206.
3. Helal I, Abderrahim E, Ben HF, et al. The first year renal function as a predictor of long term graft survival after kidney transplantation. Transplant Proc. 2009;41:648-650.
4. Refende L, Guerra J, Santana A, Mil-Homens C, Abreu F, da Costa AG. First year renal function as a predictor of kidney allograft outcome. Transplant Proc. 2009;41:846-848.
5. Rostaing L, Kamar N. mTOR inhibitor/proliferation signal inhibitor: entering or leaving the field. J Nephrol. 2010;23:133-142.
6. Schuler W, Sedrani R, Cottens F, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36-42.
7. Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation. 2005;80:244-252.
8. Tedesco-Silva H, Vitko S, Pascual J, et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int. 2007;20:27-36.
9. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimised cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomised studies. Am J Transplant. 2004;4:626-635.
10. Vitko S, Margreiter R, Weimar W, et al. Three year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2005;5:2521-2530.
11. Vitko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation. 2004;78:1532-1540.
12. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T. Everolimus and reduced exposure cyclosporine in de novo renal transplant recipients: a three-year phase 2 randomized, multicenter, open-label study. Transplantation. 2004;78:1332-1340.
13. Chan L, Greenstein S, Hardy MA, et al. Multicenter, randomised study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation. 2008;85:821-826.
14. Pascual J. Concentration-controlled everolimus (certican): combination with reduced dose calcineurin inhibitors. Transplantation. 2005;79:S76-S79.
15. Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit. 2004;26:499-505.
16. Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very low dose cyclosporine in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation. 2009;88:1194-1202.
17. Tedesco Silva H, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard exposure CsA in renal-transplant recipients. Am J Transplant. 2010;10:1-13.
18. Bertoni E, Salvadori M. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application. J Nephrol. 2009;22:457-462.
19. Letavarnier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol. 2007;2:326-333.
20. Senior PA, Paty BW, Cockfield FM, Ryan EA, Shapiro AM. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant. 2005;5:2318-2323.
21. Bertoni E, Bruschi M, Candiano G, et al. Post-transplant proteinuria associated with everolimus. Transplant Proc. 2009;41:1216-1217.